Doximity's AI Search Growth Now Has a Margin Test

Doximity said Thursday that AI Search queries rose more than 25% quarter over quarter in its fiscal first quarter, while net income margin fell to 15.5% from 36.5% a year earlier. The update gives investors a cleaner question than the headline growth rate: whether doctor workflow adoption can justify a year of lower profitability.

The company reported $156.6 million of revenue for the quarter ended June 30, up 7% year over year. It also reported adjusted EBITDA of $74.8 million, down 6%, with adjusted EBITDA margin falling to 47.7% from 54.7%.

What Doximity reported

The Doximity fiscal Q1 release republished by Yahoo Finance said workflow active prescribers grew more than 30% year over year and AI Search queries grew more than 25% quarter over quarter. Chief executive Jeff Tangney tied the engagement record to Doximity Ask, the company's clinical AI assistant.

The same release showed the cost of that push. Net income fell to $24.3 million from $53.3 million a year earlier. Non-GAAP net income fell to $55.0 million from $71.9 million, and non-GAAP diluted net income per share fell to $0.29 from $0.36.

A StockTitan SEC filing mirror lists the 8-K material-event filing and the same revenue, net-income and adjusted-EBITDA figures.

The second-order question

The result is not simply an "AI is growing" story. Doximity is trying to prove that AI can deepen its existing physician workflow rather than replace the network value that made the company useful to drug makers, hospitals and clinicians.

That distinction matters because the strongest usage figures in the release are not generic chatbot metrics. They are tied to prescriber workflow and clinical search. If those tools make doctors return more often, Doximity can defend the platform's advertising and workflow economics. If the usage fails to convert into durable revenue, the margin decline becomes harder to excuse.

The broader AI-infrastructure cycle has produced similar tradeoffs in other public-company updates, including data-center power demand and AI network capacity. Doximity's version is smaller and more vertical: it is a healthcare workflow test, not a compute-capacity race.

What comes next

Doximity guided to fiscal second-quarter adjusted EBITDA between $80.5 million and $81.5 million and full-year adjusted EBITDA between $309 million and $329 million. Those ranges make the next earnings call a margin-recovery check as much as a usage check.

For readers tracking the public-company evidence trail, the next useful markers are whether AI Search growth keeps accelerating, whether workflow active prescriber growth stays above 30%, and whether revenue growth follows before the company has to spend through more margin.

The verified claim is narrow: Doximity reported faster AI usage and prescriber-workflow growth in fiscal Q1, but the same quarter showed lower net income and adjusted EBITDA margins. The release does not prove that AI usage will become durable revenue.

This article is informational only and is not investment advice.